基于影像特征模型预测接受CAR-T治疗的B细胞淋巴瘤患者的生存、神经毒性和治疗反应
这项多中心回顾性观察研究纳入两个中心65例接受CAR-T治疗的复发/难治B细胞淋巴瘤患者,利用输注前[18F]FDG PET/CT影像特征联合临床数据建模。模型预测神经毒性AUC为0.830,预测3个月和6个月CAR-T反应AUC分别为0.754和0.818。高MTVtotal组预测中位OS为4.73个月、低MTVtotal组为37.55个月,高MTVtotal组预测中位PFS为2.73个月、低MTVtotal组为11.83个月。
要点
- 输注前[18F]FDG PET/CT影像特征联合临床变量可预测CAR-T治疗后的神经毒性和治疗反应
- MTVtotal截断值可有效分层患者,高MTVtotal组与低MTVtotal组的OS和PFS差异显著
- 联合影像特征与临床变量的预测模型准确性优于单用临床变量或单用影像特征的模型
核心结论
- 该研究成功整合影像特征与临床变量预测接受CAR-T治疗的复发/难治B细胞淋巴瘤患者结局。
- 所识别的MTVtotal截断值可有效分层患者,OS和PFS差异显著。
- 神经毒性和CAR-T反应的预测模型显示出有前景的准确性。
研究设计与样本
- 多中心回顾性观察研究,纳入两个中心65例接受CAR-T细胞治疗的复发/难治B细胞淋巴瘤患者。
- 系统收集输注前[18F]FDG PET/CT扫描和临床数据,使用Quibim平台提取影像特征。
- 影像特征包括峰度、熵、最大直径、SUV相关特征(SUVmax、SUVmean、SUVstd、SUVmedian、SUVp25、SUVp75)、总代谢肿瘤体积(MTVtotal)和总病灶糖酵解(TLGtotal)。
主要发现
- 患者中位年龄62岁(范围21-76岁),存活者中位随访10.47个月(范围0.20-45.80个月)。
- 逻辑回归模型预测神经毒性AUC为0.830。
- Cox比例风险模型预测3个月和6个月CAR-T反应AUC分别为0.754和0.818。
- 高MTVtotal组预测中位OS为4.73个月,低MTVtotal组为37.55个月。
- 高MTVtotal组预测中位PFS为2.73个月,低MTVtotal组为11.83个月。
关键数值与推荐
- 神经毒性预测模型AUC为0.830。
- 3个月CAR-T反应预测模型AUC为0.754,6个月CAR-T反应预测模型AUC为0.818。
- 高MTVtotal组预测中位OS为4.73个月,低MTVtotal组为37.55个月。
- 高MTVtotal组预测中位PFS为2.73个月,低MTVtotal组为11.83个月。
- 对所有结局,联合影像特征和临床变量的预测模型准确性优于仅用临床变量或仅用影像特征的模型。
临床怎么用
- 作者认为该综合方法有望用于风险分层和个体化治疗策略,可能成为优化复发/难治淋巴瘤患者CAR-T结局的有用工具。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This multicentre retrospective observational study aims to develop imaging-based prognostic and predictive models for relapsed/refractory (R/R) B-cell lymphoma patients undergoing CAR-T therapy by integrating clinical data and imaging features. Specifically, our aim was to predict 3- and 6-month treatment response, overall survival (OS), progression-free survival (PFS), and the occurrence of the immune effector cell-associated neurotoxicity syndrome (ICANS). RESULTS: Sixty-five patients of R/R B-cell lymphoma treated with CAR-T cells in two centres were included. Pre-infusion [18F]FDG PET/CT scans and clinical data were systematically collected, and imaging features, including kurtosis, entropy, maximum diameter, standardized uptake value (SUV) related features (SUVmax, SUVmean, SUVstd, SUVmedian, SUVp25, SUVp75), total metabolic tumour volume (MTVtotal), and total lesion glycolysis (TLGtotal), were extracted using the Quibim platform. The median age was 62 (range 21-76) years and the median follow-up for survivors was 10.47 (range 0.20-45.80) months. A logistic regression model accurately predicted neurotoxicity (AUC: 0.830), and Cox proportional-hazards models for CAR-T response at 3 and 6 months demonstrated high accuracy (AUC: 0.754 and 0.818, respectively). Median predicted OS after CAR-T therapy was 4.73 months for high MTVtotal and 37.55 months for low MTVtotal. Median predicted PFS was 2.73 months for high MTVtotal and 11.83 months for low MTVtotal. For all outcomes, predictive models, combining imaging features and clinical variables, showed improved accuracy compared to models using only clinical variables or imaging features alone. CONCLUSION: This study successfully integrates imaging features and clinical variables to predict outcomes in R/R B-cell lymphoma patients undergoing CAR-T. Notably, the identified MTVtotal cut-off effectively stratifies patients, as evidenced by significant differences in OS and PFS. Additionally, the predictive models for neurotoxicity and CAR-T response show promising accuracy. This comprehensive approach holds promise for risk stratification and personalized treatment strategies which may become a helpful tool for optimizing CAR-T outcomes in R/R lymphoma patients.
引用
- Ferrer-Lores B, Ortiz-Algarra A, Picó-Peris A, et al. Predicting survival, neurotoxicity and response in B-cell lymphoma patients treated with CAR-T therapy using an imaging features-based model. EJNMMI Res. 2024. PMID: 39567446. doi:10.1186/s13550-024-01172-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。